That's 'ALS' She Wrote: Biogen Phase III Another Bust in Space
By Randy Osborne
Staff Writer
Staff Writer
With most investor eyes focused on the waited-for FDA approval of Biogen Idec Inc.'s BG-12 for early stage multiple sclerosis (MS), the market hardly flinched at news that dexpramipexole failed in a Phase III trial for amyotrophic lateral sclerosis (ALS).
